

Ref: FOIA Reference 2021/22-374

Date: 29<sup>th</sup> November 2021

Email [foi@uhnm.nhs.uk](mailto:foi@uhnm.nhs.uk)

Dear

I am writing to acknowledge receipt of your email dated 20<sup>th</sup> October 2021 requesting information under the Freedom of Information Act (2000) regarding Breast Cancer

**Note: we have received this identical request from you twice, but will be responding once**

As of 1<sup>st</sup> November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

**Q1 I am interested in understanding how breast cancer is treated by your Trust, specifically around the usage of systemic anti-cancer therapies. Could you please help by providing the patient numbers that I have requested below?**

**How many patients have been treated for breast cancer (any stage) in the past 3 months with the systemic anti-cancer therapies listed below?**

- **Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) as a single agent**
- **Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)**
- **Abemaciclib + Fulvestrant**
- **Anthracycline (e.g. doxorubicin or epirubicin) as a single agent**
- **Atezolizumab +Nab-paclitaxel/Paclitaxel**
- **Capecitabine as a single agent**
- **Carboplatin or Cisplatin as a single agent**
- **Eribulin as a single agent or in combination**
- **Everolimus + Exemestane**
- **Fluorouracil**
- **Fulvestrant as a single agent**
- **Goserelin**
- **Lapatinib**
- **Neratinib**
- **Olaparib**
- **Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)**
- **Palbociclib + Fulvestrant**
- **Pertuzumab + Trastuzumab + Docetaxel**
- **Platinum (e.g. carboplatin or cisplatin) as a single agent**
- **Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)**

- **Ribociclib + Fulvestrant**
- **Talazoparib**
- **Tamoxifen**
- **Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent**
- **Transtuzumab as a single agent**
- **Trastuzumab emtansine**
- **Transtuzumab deruxtecan**
- **Any other active systemic anti-cancer therapy**

A1 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5

*This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.*

- Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) as a single agent = 21
- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) = 7
- Abemaciclib + Fulvestrant = 15
- Anthracycline (e.g. doxorubicin or epirubicin) as a single agent <5
- Atezolizumab +Nab-paclitaxel/Paclitaxel = 0
- Capecitabine as a single agent = 8
- Carboplatin or Cisplatin as a single agent = 0
- Eribulin as a single agent or in combination = 7
- Everolimus + Exemestane = <5
- Fluorouracil = 0
- Fulvestrant as a single agent = 16
- Goserelin = 10
- Lapatinib = 0
- Neratinib = <5
- Olaparib = 0
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) = 38
- Palbociclib + Fulvestrant = 20
- Pertuzumab + Trastuzumab + Docetaxel = 41
- Platinum (e.g. carboplatin or cisplatin) as a single agent = See above
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) =11
- Ribociclib + Fulvestrant - 1
- Talazoparib = 0
- Tamoxifen = 15
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent = 14
- Transtuzumab as a single agent = 22
- Trastuzumab emtansine = 6
- Transtuzumab deruxtecan = <5
- Any other active systemic anti-cancer therapy –
- Vinorelbine Single Agent = <5
- Vinorelbine In Combination = <5
- Epirubicin In Combination = 46
- Paclitaxel In Combination = 18

Docetaxel In Combination = 4

\*\*Please note oral medications may also be supplied in primary care. These numbers only include drugs supplied within the Trust\*\*

**Q2 In the past 3 months, how many early/locally advanced (Stages I to IIIc) breast cancer patients were treated with an Aromatase Inhibitor (anastrozole, exemestane, Letrozole) as a single agent?**

A2 Sixteen (16) \*\*Please note oral medications may also be supplied in primary care. These numbers only include drugs supplied within the Trust\*\*

\*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

***UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.***

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.


Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via [www.ico.org.uk](http://www.ico.org.uk).

If following review of the responses I can be of any further assistance please contact my secretary on 01782 671612.

Yours,

A handwritten signature in black ink on a light grey background. The signature reads "Jean Lehnert" in a cursive script.

Jean Lehnert  
**Data, Security & Protection Manager**